vs
Apellis Pharmaceuticals, Inc.（APLS）与New Fortress Energy Inc.（NFE）财务数据对比。点击上方公司名可切换其他公司
New Fortress Energy Inc.的季度营收约是Apellis Pharmaceuticals, Inc.的1.6倍（$326.2M vs $199.9M），Apellis Pharmaceuticals, Inc.净利率更高（-29.5% vs -259.7%，领先230.2%），Apellis Pharmaceuticals, Inc.同比增速更快（-5.9% vs -7.0%），Apellis Pharmaceuticals, Inc.自由现金流更多（$-14.3M vs $-134.8M），过去两年Apellis Pharmaceuticals, Inc.的营收复合增速更高（7.7% vs -26.8%）
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
New Fortress Energy Inc.是一家全球能源基础设施企业，主要开发、持有并运营液化天然气进出口终端、天然气供应网络及低碳能源项目，服务美洲、加勒比地区客户，致力于提供低成本、低排放的能源解决方案。
APLS vs NFE — 直观对比
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $199.9M | $326.2M |
| 净利润 | $-59.0M | $-847.1M |
| 毛利率 | — | 35.5% |
| 营业利润率 | -25.6% | -193.0% |
| 净利率 | -29.5% | -259.7% |
| 营收同比 | -5.9% | -7.0% |
| 净利润同比 | -62.2% | -277.4% |
| 每股收益（稀释后） | $-0.40 | $-3.03 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $199.9M | $326.2M | ||
| Q3 25 | $458.6M | $240.3M | ||
| Q2 25 | $178.5M | $228.1M | ||
| Q1 25 | $166.8M | $384.9M | ||
| Q4 24 | $212.5M | $350.7M | ||
| Q3 24 | $196.8M | $446.0M | ||
| Q2 24 | $199.7M | $291.2M | ||
| Q1 24 | $172.3M | $609.5M |
| Q4 25 | $-59.0M | $-847.1M | ||
| Q3 25 | $215.7M | $-263.0M | ||
| Q2 25 | $-42.2M | $-546.5M | ||
| Q1 25 | $-92.2M | $-175.4M | ||
| Q4 24 | $-36.4M | $-224.4M | ||
| Q3 24 | $-57.4M | $9.3M | ||
| Q2 24 | $-37.7M | $-88.9M | ||
| Q1 24 | $-66.4M | $54.1M |
| Q4 25 | — | 35.5% | ||
| Q3 25 | — | 18.1% | ||
| Q2 25 | — | 8.4% | ||
| Q1 25 | — | 21.4% | ||
| Q4 24 | — | 17.6% | ||
| Q3 24 | — | 27.1% | ||
| Q2 24 | — | 23.8% | ||
| Q1 24 | — | 62.4% |
| Q4 25 | -25.6% | -193.0% | ||
| Q3 25 | 48.7% | -37.4% | ||
| Q2 25 | -18.6% | -170.3% | ||
| Q1 25 | -50.0% | -3.3% | ||
| Q4 24 | -12.3% | 65.0% | ||
| Q3 24 | -24.0% | 17.8% | ||
| Q2 24 | -14.7% | 12.3% | ||
| Q1 24 | -36.0% | 30.4% |
| Q4 25 | -29.5% | -259.7% | ||
| Q3 25 | 47.0% | -109.4% | ||
| Q2 25 | -23.6% | -239.6% | ||
| Q1 25 | -55.3% | -45.6% | ||
| Q4 24 | -17.1% | -64.0% | ||
| Q3 24 | -29.2% | 2.1% | ||
| Q2 24 | -18.9% | -30.5% | ||
| Q1 24 | -38.5% | 8.9% |
| Q4 25 | $-0.40 | $-3.03 | ||
| Q3 25 | $1.67 | $-0.96 | ||
| Q2 25 | $-0.33 | $-1.99 | ||
| Q1 25 | $-0.74 | $-0.65 | ||
| Q4 24 | $-0.30 | $-1.10 | ||
| Q3 24 | $-0.46 | $0.03 | ||
| Q2 24 | $-0.30 | $-0.42 | ||
| Q1 24 | $-0.54 | $0.23 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $466.2M | $226.5M |
| 总债务越低越好 | — | $8.2B |
| 股东权益账面价值 | $370.1M | $182.6M |
| 总资产 | $1.1B | $10.6B |
| 负债/权益比越低杠杆越低 | — | 44.78× |
8季度趋势，按日历期对齐
| Q4 25 | $466.2M | $226.5M | ||
| Q3 25 | $479.2M | $145.2M | ||
| Q2 25 | $370.0M | $551.1M | ||
| Q1 25 | $358.4M | $447.9M | ||
| Q4 24 | $411.3M | $492.9M | ||
| Q3 24 | $396.9M | $90.8M | ||
| Q2 24 | $360.1M | $133.0M | ||
| Q1 24 | $325.9M | $143.5M |
| Q4 25 | — | $8.2B | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $8.9B | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | $93.1M | — |
| Q4 25 | $370.1M | $182.6M | ||
| Q3 25 | $401.2M | $1.1B | ||
| Q2 25 | $156.3M | $1.3B | ||
| Q1 25 | $164.2M | $1.8B | ||
| Q4 24 | $228.5M | $1.9B | ||
| Q3 24 | $237.1M | $1.6B | ||
| Q2 24 | $264.3M | $1.6B | ||
| Q1 24 | $266.7M | $1.7B |
| Q4 25 | $1.1B | $10.6B | ||
| Q3 25 | $1.1B | $12.0B | ||
| Q2 25 | $821.4M | $12.0B | ||
| Q1 25 | $807.3M | $13.1B | ||
| Q4 24 | $885.1M | $12.9B | ||
| Q3 24 | $901.9M | $12.0B | ||
| Q2 24 | $904.5M | $11.4B | ||
| Q1 24 | $831.9M | $10.9B |
| Q4 25 | — | 44.78× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 4.74× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 0.35× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-14.2M | $-76.2M |
| 自由现金流经营现金流 - 资本支出 | $-14.3M | $-134.8M |
| 自由现金流率自由现金流/营收 | -7.1% | -41.3% |
| 资本支出强度资本支出/营收 | 0.1% | 18.0% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $45.0M | $-1.4B |
8季度趋势，按日历期对齐
| Q4 25 | $-14.2M | $-76.2M | ||
| Q3 25 | $108.5M | $-171.0M | ||
| Q2 25 | $4.4M | $-329.0M | ||
| Q1 25 | $-53.4M | $-7.2M | ||
| Q4 24 | $19.4M | $445.3M | ||
| Q3 24 | $34.1M | $-20.0M | ||
| Q2 24 | $-8.3M | $113.9M | ||
| Q1 24 | $-133.0M | $63.0M |
| Q4 25 | $-14.3M | $-134.8M | ||
| Q3 25 | $108.3M | $-231.6M | ||
| Q2 25 | $4.4M | $-726.7M | ||
| Q1 25 | $-53.4M | $-262.3M | ||
| Q4 24 | $19.3M | $-210.3M | ||
| Q3 24 | — | $-367.0M | ||
| Q2 24 | $-8.4M | $-493.2M | ||
| Q1 24 | $-133.3M | $-457.9M |
| Q4 25 | -7.1% | -41.3% | ||
| Q3 25 | 23.6% | -96.4% | ||
| Q2 25 | 2.5% | -318.6% | ||
| Q1 25 | -32.0% | -68.2% | ||
| Q4 24 | 9.1% | -60.0% | ||
| Q3 24 | — | -82.3% | ||
| Q2 24 | -4.2% | -169.3% | ||
| Q1 24 | -77.3% | -75.1% |
| Q4 25 | 0.1% | 18.0% | ||
| Q3 25 | 0.0% | 25.2% | ||
| Q2 25 | 0.0% | 174.4% | ||
| Q1 25 | 0.0% | 66.3% | ||
| Q4 24 | 0.0% | 187.0% | ||
| Q3 24 | 0.0% | 77.8% | ||
| Q2 24 | 0.0% | 208.4% | ||
| Q1 24 | 0.2% | 85.5% |
| Q4 25 | — | — | ||
| Q3 25 | 0.50× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | -2.15× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 1.16× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
NFE
暂无分部数据
